Search | Clinical Trials Finder

Conditions: Pre Diabetes, Postpartum Disorder
Interventions: Semaglutide Pen Injector [Ozempic], Placebo semaglutide pen injector; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Overweight or Obesity, Atrial Fibrillation
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Phoenix, Arizona • Chicago, Illinois

Conditions: Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid
Interventions: Semaglutide Pen Injector, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Baltimore, Maryland • Fall River, Massachusetts • New York, New York + 1 more

Conditions: Lower Back Pain, Obesity (BMI>30), Chronic Lower Back Pain, glp1 Agonist
Interventions: Semaglutide (administered by PDS290 pen-injector), Placebo (administered by PDS290 pen-injector); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 85 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 2
States / cities: Birmingham, Alabama • St Louis, Missouri

Conditions: Diabetes Mellitus, Type 2
Interventions: Albiglutide Liquid Auto-injector, Albiglutide Lyophilized DCC Pen Injector, Placebo Liquid Auto-injector, Placebo Lyophilized DCC Pen injector; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Overweight, Obesity, Type 2 Diabetes
Interventions: Cagrilintide, Placebo (matched to Cagrilintide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 18 more

Conditions: Asthma
Interventions: Semaglutide Pen Injector 2.4mg weekly, Placebo; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Peripheral Arterial Disease
Interventions: Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months., Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.; Drug · Other
Lead sponsor: Leonardo Clavijo; Other
Eligibility: 40 Years to 85 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Obesity, Overweight
Interventions: Cagrilintide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Walnut Creek, California • Aurora, Colorado • Orlando, Florida + 6 more

Conditions: Opiate Substitution Treatment, Opioid-Related Disorders
Interventions: Liraglutide Pen Injector, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity
Interventions: Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution; Drug
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Danville, Pennsylvania • Wilkes-Barre, Pennsylvania

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone; Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 8
States / cities: Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more

Conditions: Alcohol Use Disorder
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Oklahoma State University Center for Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Heart Failure
Interventions: Ziltivekimab, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 4,899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 172
States / cities: Alexander City, Alabama • Fairhope, Alabama • Huntsville, Alabama + 141 more

Conditions: Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 35 Years and older
Enrollment: 235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Lyophilized albiglutide DCC pen injector, Lyophilized albiglutide DCC pen injector matching placebo, Albiglutide liquid auto-injector, Albiglutide liquid auto-injector matching placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 70
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 62 more

Conditions: Overweight, Obese, Type 1 Diabetes Mellitus
Interventions: CT-868, CT-868 Pen Injector, CT-868 Pen Injector, Placebo; Drug · Device
Lead sponsor: Carmot Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 22
States / cities: Concord, California • Escondido, California • Aurora, Colorado + 17 more

Conditions: Bipolar Disorder, Obesity
Interventions: LIRAGLUTIDE, Placebo; Drug · Other
Lead sponsor: Lindner Center of HOPE; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Hypercholesterolaemia
Interventions: Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 14
States / cities: Bell Gardens, California • Newport Beach, California • Northridge, California + 8 more

Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
Interventions: Semaglutide Pen Injector, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 10 Years to 21 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
Interventions: CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 20
States / cities: La Mesa, California • San Diego, California • Miami, Florida + 14 more

Conditions: Obesity
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 22
States / cities: Miramar, Florida • Orlando, Florida • Conyers, Georgia + 19 more

Conditions: Obesity
Interventions: Saxenda®, Placebo; Drug · Other
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Lubbock, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Lixisenatide (AVE0010), Placebo, Pen auto-injector, Sulfonylurea, Metformin; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Search by objective public record fields.

Treatment to Regress to Normoglycemia in Women with a Recent History of GDM

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

GLP-1R Agonist Treatment for Opioid Use Disorder

Semaglutide for Low Back Pain

Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)

Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Semaglutide Therapy for Alcohol Reduction - Tulsa

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Impact of Liraglutide 3.0 on Body Fat Distribution

Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

A Study of CT-868 in Type 1 Diabetes Mellitus

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea